Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays

George Sandusky, K. S. Mintze, S. E. Pratt, A. H. Dantzig

Research output: Contribution to journalArticle

90 Citations (Scopus)

Abstract

Aims: Using tissue microarrays, this study analysed the expression of the multidrug resistance protein, MRP2, by immunohistochemistry with two different MRP2 antibodies. This is the first study to address the expression of MRP2 in various common human neoplasms. Methods and results: Immunohistochemistry was performed on zinc formalin-fixed tissue to evaluate normal tissues and carcinomas using two antibodies against MRP2 (EAG5, a polyclonal antibody, and M2-lll-6, a monoclonal antibody). Immunostaining was localized in neoplastic cells mainly on the cell membrane with M2-lll-6 and cell membrane and cytoplasm with EAG5. In normal tissues MRP2 was expressed in liver, gastrointestinal tract, and kidney tubular epithelial cells with both antibodies. MRP2 was seen in nine of 22 renal cell carcinomas, eight of 13 gastric carcinomas, 25 of 49 breast carcinomas, 14 of 32 lung carcinomas, 39 of 50 colon carcinomas, and 16 of 17 ovarian carcinomas. There was <10% variability between the two antibodies. MRP2 expression was highest in moderate to poorly differentiated tumours from colon, lung, gastric, and ovarian carcinomas and in grade 2 and 3 breast and renal carcinomas. Conclusion: The expression of MRP2 in many solid human tumours indicates that inherent drug resistance may play an important role as a biomarker for predictive chemotherapy treatment.

Original languageEnglish (US)
Pages (from-to)65-74
Number of pages10
JournalHistopathology
Volume41
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Carcinoma
Antibodies
Stomach
Colon
Immunohistochemistry
Cell Membrane
Breast Neoplasms
P-Glycoproteins
Kidney
Neoplasms
Lung
multidrug resistance-associated protein 2
Renal Cell Carcinoma
Drug Resistance
Formaldehyde
Gastrointestinal Tract
Zinc
Cytoplasm
Biomarkers
Epithelial Cells

Keywords

  • Immunohistochemistry
  • Microarrays
  • Multidrug resistance
  • Tissues
  • Tumours

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Cell Biology

Cite this

Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. / Sandusky, George; Mintze, K. S.; Pratt, S. E.; Dantzig, A. H.

In: Histopathology, Vol. 41, No. 1, 2002, p. 65-74.

Research output: Contribution to journalArticle

@article{e8c1b5ccc6d74f4ab8f12d5e9cc27cdb,
title = "Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays",
abstract = "Aims: Using tissue microarrays, this study analysed the expression of the multidrug resistance protein, MRP2, by immunohistochemistry with two different MRP2 antibodies. This is the first study to address the expression of MRP2 in various common human neoplasms. Methods and results: Immunohistochemistry was performed on zinc formalin-fixed tissue to evaluate normal tissues and carcinomas using two antibodies against MRP2 (EAG5, a polyclonal antibody, and M2-lll-6, a monoclonal antibody). Immunostaining was localized in neoplastic cells mainly on the cell membrane with M2-lll-6 and cell membrane and cytoplasm with EAG5. In normal tissues MRP2 was expressed in liver, gastrointestinal tract, and kidney tubular epithelial cells with both antibodies. MRP2 was seen in nine of 22 renal cell carcinomas, eight of 13 gastric carcinomas, 25 of 49 breast carcinomas, 14 of 32 lung carcinomas, 39 of 50 colon carcinomas, and 16 of 17 ovarian carcinomas. There was <10{\%} variability between the two antibodies. MRP2 expression was highest in moderate to poorly differentiated tumours from colon, lung, gastric, and ovarian carcinomas and in grade 2 and 3 breast and renal carcinomas. Conclusion: The expression of MRP2 in many solid human tumours indicates that inherent drug resistance may play an important role as a biomarker for predictive chemotherapy treatment.",
keywords = "Immunohistochemistry, Microarrays, Multidrug resistance, Tissues, Tumours",
author = "George Sandusky and Mintze, {K. S.} and Pratt, {S. E.} and Dantzig, {A. H.}",
year = "2002",
doi = "10.1046/j.1365-2559.2002.01403.x",
language = "English (US)",
volume = "41",
pages = "65--74",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays

AU - Sandusky, George

AU - Mintze, K. S.

AU - Pratt, S. E.

AU - Dantzig, A. H.

PY - 2002

Y1 - 2002

N2 - Aims: Using tissue microarrays, this study analysed the expression of the multidrug resistance protein, MRP2, by immunohistochemistry with two different MRP2 antibodies. This is the first study to address the expression of MRP2 in various common human neoplasms. Methods and results: Immunohistochemistry was performed on zinc formalin-fixed tissue to evaluate normal tissues and carcinomas using two antibodies against MRP2 (EAG5, a polyclonal antibody, and M2-lll-6, a monoclonal antibody). Immunostaining was localized in neoplastic cells mainly on the cell membrane with M2-lll-6 and cell membrane and cytoplasm with EAG5. In normal tissues MRP2 was expressed in liver, gastrointestinal tract, and kidney tubular epithelial cells with both antibodies. MRP2 was seen in nine of 22 renal cell carcinomas, eight of 13 gastric carcinomas, 25 of 49 breast carcinomas, 14 of 32 lung carcinomas, 39 of 50 colon carcinomas, and 16 of 17 ovarian carcinomas. There was <10% variability between the two antibodies. MRP2 expression was highest in moderate to poorly differentiated tumours from colon, lung, gastric, and ovarian carcinomas and in grade 2 and 3 breast and renal carcinomas. Conclusion: The expression of MRP2 in many solid human tumours indicates that inherent drug resistance may play an important role as a biomarker for predictive chemotherapy treatment.

AB - Aims: Using tissue microarrays, this study analysed the expression of the multidrug resistance protein, MRP2, by immunohistochemistry with two different MRP2 antibodies. This is the first study to address the expression of MRP2 in various common human neoplasms. Methods and results: Immunohistochemistry was performed on zinc formalin-fixed tissue to evaluate normal tissues and carcinomas using two antibodies against MRP2 (EAG5, a polyclonal antibody, and M2-lll-6, a monoclonal antibody). Immunostaining was localized in neoplastic cells mainly on the cell membrane with M2-lll-6 and cell membrane and cytoplasm with EAG5. In normal tissues MRP2 was expressed in liver, gastrointestinal tract, and kidney tubular epithelial cells with both antibodies. MRP2 was seen in nine of 22 renal cell carcinomas, eight of 13 gastric carcinomas, 25 of 49 breast carcinomas, 14 of 32 lung carcinomas, 39 of 50 colon carcinomas, and 16 of 17 ovarian carcinomas. There was <10% variability between the two antibodies. MRP2 expression was highest in moderate to poorly differentiated tumours from colon, lung, gastric, and ovarian carcinomas and in grade 2 and 3 breast and renal carcinomas. Conclusion: The expression of MRP2 in many solid human tumours indicates that inherent drug resistance may play an important role as a biomarker for predictive chemotherapy treatment.

KW - Immunohistochemistry

KW - Microarrays

KW - Multidrug resistance

KW - Tissues

KW - Tumours

UR - http://www.scopus.com/inward/record.url?scp=0035985610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035985610&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2559.2002.01403.x

DO - 10.1046/j.1365-2559.2002.01403.x

M3 - Article

C2 - 12121239

AN - SCOPUS:0035985610

VL - 41

SP - 65

EP - 74

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -